Volume 31, Number 9—September 2025
CME ACTIVITY - Research
Severe Group A Streptococcus Infection among Children, France, 2022–2024
Table 2
Management of severe group A Streptococcus infections among 402 children, France, 2022–2024
Treatment | No. (%) |
---|---|
Oxygen therapy | 120 (30) |
Conventional | 45 (11) |
High-flow | 27 (7) |
Noninvasive ventilation | 11 (3) |
Invasive ventilation | 32 (8) |
Extracorporeal membrane oxygenation |
5 (1) |
Hemodynamic therapy | 97 (24) |
Fluid resuscitation | 97 (24) |
Vasopressor treatment |
50 (12) |
First-line antibiotic treatment | |
Amoxicillin/clavulanate | 138 (34) |
Third generation cephalosporin | 141 (35) |
β-lactam + clindamycin |
173 (43) |
Adjunctive therapies | |
Intravenous Immunoglobulins | 17 (4) |
Hydrocortisone hemisuccinate for shock | 19 (4) |
1Additional members who contributed data are listed at the end of this article.
Page created: July 11, 2025
Page updated: August 21, 2025
Page reviewed: August 21, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.